✦ LIBER ✦

Efficacy, safety and tolerability of a new intravenous immune globulin, 10% liquid, triple virus reduced (IGIV,10%TVR) in patients with primary immunodeficiency (PID)

✍ Scribed by Church, J.A.; Leibl, H.; Stein, M.R.; Melamed, I.R.; Rubinstein, A.; Schneider, L.C.; Wasserman, R.L.; Pavlova, B.G.; Birthistle, K.; Mancini, M.; Bitman, B.; Moore-Perry, K.; Ehrlich, H.J.

Book ID: 119275586
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 26 KB
Volume: 115
Category: Article
ISSN: 1097-6825
DOI: 10.1016/j.jaci.2004.12.650

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Efficacy, Safety and Tolerability of a N

Efficacy, Safety and Tolerability of a New 10% Liquid Intravenous Immune Globulin [IGIV 10%] in Patients with Primary Immunodeficiency

✍ Joseph A. Church; Heinz Leibl; Mark R. Stein; Isaac R. Melamed; Arye Rubinstein; 📂 Article 📅 2006 🏛 Springer 🌐 English ⚖ 443 KB

Pathogen safety profile of a new 10% liq

Pathogen safety profile of a new 10% liquid, triple virus reduced intravenous immune globulin product, new generation IGIV (NG IGIV)—Further studies

✍ Kreil, T.R.; Poelsler, G.; Bailey, A.C.; Teschner, W.; Schwarz, H.P. 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 31 KB

Pharmacokinetics and Safety of Subcutane

Pharmacokinetics and Safety of Subcutaneous Immune Globulin (Human), 10% Caprylate/Chromatography Purified (IGIV-C) in Patients with Primary Immunodeficiency Disease (PID)

✍ Levy, R.; Chen, J.; Roberts, R.; Sorrells, S.; Stark, D.; Tracy, J.; Wasserman, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 45 KB

Safety, Efficacy and Pharmacokinetics of

Safety, Efficacy and Pharmacokinetics of a New 10% Liquid Intravenous Immunoglobulin (IVIG) in Patients with Primary Immunodeficiency

✍ Wasserman, Richard L.; Church, Joseph A.; Stein, Mark; Moy, James; White, Martha 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 154 KB

Efficacy, Safety, and Pharmacokinetics o

Efficacy, Safety, and Pharmacokinetics of a 10% Liquid Immune Globulin Preparation (GAMMAGARD LIQUID, 10%) Administered Subcutaneously in Subjects with Primary Immunodeficiency Disease

✍ Richard L. Wasserman; Isaac Melamed; Lisa Kobrynski; Steven D. Strausbaugh; Mark 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 213 KB

Safety, efficacy, tolerability, and phar

Safety, efficacy, tolerability, and pharmacokinetics of a new liquid intravenous immunoglobulin (IVIG) in comparison to Sandoglobulin® in patients with primary immunodeficiencies (PID)

✍ Borte, M.; Wahn, U.; Farber, C.; Bernatowska, E.; Adams, C.; Andresen, I.; Bende 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 130 KB